nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—PLA2G4A—Raltitrexed—Methotrexate—lymphatic system cancer	0.0176	0.455	CbGdCrCtD
Orlistat—FASN—Azacitidine—Fludarabine—lymphatic system cancer	0.0108	0.28	CbGdCrCtD
Orlistat—FASN—Azacitidine—Cytarabine—lymphatic system cancer	0.0102	0.265	CbGdCrCtD
Orlistat—Oedema—Fludarabine—lymphatic system cancer	0.00337	0.00351	CcSEcCtD
Orlistat—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00337	0.00351	CcSEcCtD
Orlistat—Infection—Fludarabine—lymphatic system cancer	0.00335	0.00348	CcSEcCtD
Orlistat—Decreased appetite—Teniposide—lymphatic system cancer	0.00334	0.00347	CcSEcCtD
Orlistat—Renal failure—Carmustine—lymphatic system cancer	0.00333	0.00346	CcSEcCtD
Orlistat—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00332	0.00345	CcSEcCtD
Orlistat—Vomiting—Mechlorethamine—lymphatic system cancer	0.00331	0.00344	CcSEcCtD
Orlistat—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00331	0.00344	CcSEcCtD
Orlistat—Urinary tract infection—Carmustine—lymphatic system cancer	0.00329	0.00342	CcSEcCtD
Orlistat—Rash—Mechlorethamine—lymphatic system cancer	0.00328	0.00341	CcSEcCtD
Orlistat—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00328	0.00341	CcSEcCtD
Orlistat—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00328	0.00341	CcSEcCtD
Orlistat—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00326	0.00339	CcSEcCtD
Orlistat—Depression—Vincristine—lymphatic system cancer	0.00322	0.00335	CcSEcCtD
Orlistat—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00317	0.00329	CcSEcCtD
Orlistat—Feeling abnormal—Teniposide—lymphatic system cancer	0.00316	0.00329	CcSEcCtD
Orlistat—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00314	0.00326	CcSEcCtD
Orlistat—Renal failure—Mitoxantrone—lymphatic system cancer	0.00309	0.00322	CcSEcCtD
Orlistat—Nausea—Mechlorethamine—lymphatic system cancer	0.00309	0.00322	CcSEcCtD
Orlistat—Alopecia—Bleomycin—lymphatic system cancer	0.00308	0.0032	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00307	0.0032	CcSEcCtD
Orlistat—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00306	0.00318	CcSEcCtD
Orlistat—Haemoglobin—Carmustine—lymphatic system cancer	0.00305	0.00318	CcSEcCtD
Orlistat—Urticaria—Teniposide—lymphatic system cancer	0.00305	0.00317	CcSEcCtD
Orlistat—Haemorrhage—Carmustine—lymphatic system cancer	0.00304	0.00316	CcSEcCtD
Orlistat—Abdominal pain—Teniposide—lymphatic system cancer	0.00303	0.00315	CcSEcCtD
Orlistat—Body temperature increased—Teniposide—lymphatic system cancer	0.00303	0.00315	CcSEcCtD
Orlistat—Paraesthesia—Fludarabine—lymphatic system cancer	0.00303	0.00315	CcSEcCtD
Orlistat—Oedema peripheral—Carmustine—lymphatic system cancer	0.00299	0.00311	CcSEcCtD
Orlistat—Dyspepsia—Fludarabine—lymphatic system cancer	0.00297	0.00309	CcSEcCtD
Orlistat—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00295	0.00307	CcSEcCtD
Orlistat—Decreased appetite—Fludarabine—lymphatic system cancer	0.00293	0.00305	CcSEcCtD
Orlistat—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00291	0.00303	CcSEcCtD
Orlistat—Fatigue—Fludarabine—lymphatic system cancer	0.00291	0.00302	CcSEcCtD
Orlistat—Pain—Fludarabine—lymphatic system cancer	0.00288	0.003	CcSEcCtD
Orlistat—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00286	0.00298	CcSEcCtD
Orlistat—Urethral disorder—Vincristine—lymphatic system cancer	0.00284	0.00296	CcSEcCtD
Orlistat—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00284	0.00295	CcSEcCtD
Orlistat—Hypersensitivity—Teniposide—lymphatic system cancer	0.00283	0.00294	CcSEcCtD
Orlistat—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00282	0.00294	CcSEcCtD
Orlistat—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00282	0.00294	CcSEcCtD
Orlistat—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00281	0.00292	CcSEcCtD
Orlistat—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.0028	0.00292	CcSEcCtD
Orlistat—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.0028	0.00291	CcSEcCtD
Orlistat—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00278	0.00289	CcSEcCtD
Orlistat—Asthenia—Teniposide—lymphatic system cancer	0.00275	0.00286	CcSEcCtD
Orlistat—Malaise—Bleomycin—lymphatic system cancer	0.00273	0.00284	CcSEcCtD
Orlistat—Pruritus—Teniposide—lymphatic system cancer	0.00271	0.00282	CcSEcCtD
Orlistat—Alopecia—Carmustine—lymphatic system cancer	0.00268	0.00279	CcSEcCtD
Orlistat—Body temperature increased—Fludarabine—lymphatic system cancer	0.00267	0.00277	CcSEcCtD
Orlistat—Mental disorder—Carmustine—lymphatic system cancer	0.00266	0.00277	CcSEcCtD
Orlistat—Vaginal infection—Methotrexate—lymphatic system cancer	0.00265	0.00275	CcSEcCtD
Orlistat—Malnutrition—Carmustine—lymphatic system cancer	0.00264	0.00275	CcSEcCtD
Orlistat—Cough—Bleomycin—lymphatic system cancer	0.00264	0.00275	CcSEcCtD
Orlistat—Diarrhoea—Teniposide—lymphatic system cancer	0.00263	0.00273	CcSEcCtD
Orlistat—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00261	0.00272	CcSEcCtD
Orlistat—Chest pain—Bleomycin—lymphatic system cancer	0.00258	0.00268	CcSEcCtD
Orlistat—Myalgia—Bleomycin—lymphatic system cancer	0.00258	0.00268	CcSEcCtD
Orlistat—Alopecia—Vincristine—lymphatic system cancer	0.00256	0.00267	CcSEcCtD
Orlistat—Back pain—Carmustine—lymphatic system cancer	0.00256	0.00266	CcSEcCtD
Orlistat—Discomfort—Bleomycin—lymphatic system cancer	0.00255	0.00265	CcSEcCtD
Orlistat—Mental disorder—Vincristine—lymphatic system cancer	0.00254	0.00264	CcSEcCtD
Orlistat—Urine output increased—Methotrexate—lymphatic system cancer	0.00253	0.00263	CcSEcCtD
Orlistat—Neoplasm—Methotrexate—lymphatic system cancer	0.00253	0.00263	CcSEcCtD
Orlistat—Alopecia—Mitoxantrone—lymphatic system cancer	0.0025	0.0026	CcSEcCtD
Orlistat—Vision blurred—Carmustine—lymphatic system cancer	0.00249	0.00259	CcSEcCtD
Orlistat—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00248	0.00258	CcSEcCtD
Orlistat—Oedema—Bleomycin—lymphatic system cancer	0.00247	0.00257	CcSEcCtD
Orlistat—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00247	0.00257	CcSEcCtD
Orlistat—Infection—Bleomycin—lymphatic system cancer	0.00246	0.00255	CcSEcCtD
Orlistat—Back pain—Vincristine—lymphatic system cancer	0.00244	0.00254	CcSEcCtD
Orlistat—Vomiting—Teniposide—lymphatic system cancer	0.00244	0.00254	CcSEcCtD
Orlistat—Asthenia—Fludarabine—lymphatic system cancer	0.00242	0.00252	CcSEcCtD
Orlistat—Rash—Teniposide—lymphatic system cancer	0.00242	0.00252	CcSEcCtD
Orlistat—Dermatitis—Teniposide—lymphatic system cancer	0.00242	0.00251	CcSEcCtD
Orlistat—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00241	0.0025	CcSEcCtD
Orlistat—Headache—Teniposide—lymphatic system cancer	0.0024	0.0025	CcSEcCtD
Orlistat—Pruritus—Fludarabine—lymphatic system cancer	0.00239	0.00248	CcSEcCtD
Orlistat—Back pain—Mitoxantrone—lymphatic system cancer	0.00238	0.00247	CcSEcCtD
Orlistat—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00234	0.00243	CcSEcCtD
Orlistat—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00232	0.00241	CcSEcCtD
Orlistat—Polyuria—Methotrexate—lymphatic system cancer	0.00232	0.00241	CcSEcCtD
Orlistat—Diarrhoea—Fludarabine—lymphatic system cancer	0.00231	0.0024	CcSEcCtD
Orlistat—Convulsion—Carmustine—lymphatic system cancer	0.00229	0.00238	CcSEcCtD
Orlistat—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00228	0.00237	CcSEcCtD
Orlistat—Nausea—Teniposide—lymphatic system cancer	0.00228	0.00237	CcSEcCtD
Orlistat—Vertigo—Vincristine—lymphatic system cancer	0.00227	0.00236	CcSEcCtD
Orlistat—Hepatic failure—Methotrexate—lymphatic system cancer	0.00226	0.00235	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00225	0.00234	CcSEcCtD
Orlistat—Chest pain—Carmustine—lymphatic system cancer	0.00225	0.00234	CcSEcCtD
Orlistat—Myalgia—Carmustine—lymphatic system cancer	0.00225	0.00234	CcSEcCtD
Orlistat—Anxiety—Carmustine—lymphatic system cancer	0.00224	0.00233	CcSEcCtD
Orlistat—Paraesthesia—Bleomycin—lymphatic system cancer	0.00222	0.00231	CcSEcCtD
Orlistat—Malaise—Mitoxantrone—lymphatic system cancer	0.00222	0.00231	CcSEcCtD
Orlistat—Convulsion—Vincristine—lymphatic system cancer	0.00219	0.00227	CcSEcCtD
Orlistat—Oedema—Carmustine—lymphatic system cancer	0.00216	0.00224	CcSEcCtD
Orlistat—Decreased appetite—Bleomycin—lymphatic system cancer	0.00215	0.00224	CcSEcCtD
Orlistat—Myalgia—Vincristine—lymphatic system cancer	0.00215	0.00224	CcSEcCtD
Orlistat—Cough—Mitoxantrone—lymphatic system cancer	0.00215	0.00223	CcSEcCtD
Orlistat—Infection—Carmustine—lymphatic system cancer	0.00214	0.00223	CcSEcCtD
Orlistat—Vomiting—Fludarabine—lymphatic system cancer	0.00214	0.00223	CcSEcCtD
Orlistat—Convulsion—Mitoxantrone—lymphatic system cancer	0.00213	0.00222	CcSEcCtD
Orlistat—Rash—Fludarabine—lymphatic system cancer	0.00213	0.00221	CcSEcCtD
Orlistat—Dermatitis—Fludarabine—lymphatic system cancer	0.00212	0.00221	CcSEcCtD
Orlistat—Pain—Bleomycin—lymphatic system cancer	0.00211	0.0022	CcSEcCtD
Orlistat—Headache—Fludarabine—lymphatic system cancer	0.00211	0.0022	CcSEcCtD
Orlistat—Myalgia—Mitoxantrone—lymphatic system cancer	0.00209	0.00218	CcSEcCtD
Orlistat—Chest pain—Mitoxantrone—lymphatic system cancer	0.00209	0.00218	CcSEcCtD
Orlistat—Anxiety—Mitoxantrone—lymphatic system cancer	0.00209	0.00217	CcSEcCtD
Orlistat—Discomfort—Mitoxantrone—lymphatic system cancer	0.00207	0.00215	CcSEcCtD
Orlistat—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00206	0.00214	CcSEcCtD
Orlistat—Oedema—Vincristine—lymphatic system cancer	0.00206	0.00214	CcSEcCtD
Orlistat—Infection—Vincristine—lymphatic system cancer	0.00205	0.00213	CcSEcCtD
Orlistat—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00204	0.00212	CcSEcCtD
Orlistat—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00203	0.00212	CcSEcCtD
Orlistat—Nervous system disorder—Vincristine—lymphatic system cancer	0.00202	0.0021	CcSEcCtD
Orlistat—Oedema—Mitoxantrone—lymphatic system cancer	0.00201	0.00209	CcSEcCtD
Orlistat—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00201	0.00209	CcSEcCtD
Orlistat—Nausea—Fludarabine—lymphatic system cancer	0.002	0.00208	CcSEcCtD
Orlistat—Infection—Mitoxantrone—lymphatic system cancer	0.00199	0.00207	CcSEcCtD
Orlistat—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00199	0.00207	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00197	0.00205	CcSEcCtD
Orlistat—Urticaria—Bleomycin—lymphatic system cancer	0.00196	0.00204	CcSEcCtD
Orlistat—Body temperature increased—Bleomycin—lymphatic system cancer	0.00195	0.00203	CcSEcCtD
Orlistat—Insomnia—Carmustine—lymphatic system cancer	0.00195	0.00203	CcSEcCtD
Orlistat—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00195	0.00203	CcSEcCtD
Orlistat—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00194	0.00202	CcSEcCtD
Orlistat—Paraesthesia—Carmustine—lymphatic system cancer	0.00194	0.00202	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00188	0.00195	CcSEcCtD
Orlistat—Decreased appetite—Carmustine—lymphatic system cancer	0.00188	0.00195	CcSEcCtD
Orlistat—Insomnia—Vincristine—lymphatic system cancer	0.00186	0.00194	CcSEcCtD
Orlistat—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00186	0.00194	CcSEcCtD
Orlistat—Paraesthesia—Vincristine—lymphatic system cancer	0.00185	0.00192	CcSEcCtD
Orlistat—Pain—Carmustine—lymphatic system cancer	0.00185	0.00192	CcSEcCtD
Orlistat—Breast disorder—Methotrexate—lymphatic system cancer	0.00184	0.00191	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00183	0.0019	CcSEcCtD
Orlistat—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00182	0.00189	CcSEcCtD
Orlistat—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.0018	0.00187	CcSEcCtD
Orlistat—Decreased appetite—Vincristine—lymphatic system cancer	0.00179	0.00186	CcSEcCtD
Orlistat—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00178	0.00185	CcSEcCtD
Orlistat—Feeling abnormal—Carmustine—lymphatic system cancer	0.00178	0.00185	CcSEcCtD
Orlistat—Fatigue—Vincristine—lymphatic system cancer	0.00178	0.00185	CcSEcCtD
Orlistat—Asthenia—Bleomycin—lymphatic system cancer	0.00177	0.00185	CcSEcCtD
Orlistat—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00177	0.00184	CcSEcCtD
Orlistat—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00176	0.00184	CcSEcCtD
Orlistat—Pain—Vincristine—lymphatic system cancer	0.00176	0.00183	CcSEcCtD
Orlistat—Asthma—Methotrexate—lymphatic system cancer	0.00176	0.00183	CcSEcCtD
Orlistat—Pruritus—Bleomycin—lymphatic system cancer	0.00175	0.00182	CcSEcCtD
Orlistat—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00174	0.00181	CcSEcCtD
Orlistat—Fatigue—Mitoxantrone—lymphatic system cancer	0.00173	0.0018	CcSEcCtD
Orlistat—Pancreatitis—Methotrexate—lymphatic system cancer	0.00172	0.00179	CcSEcCtD
Orlistat—Pain—Mitoxantrone—lymphatic system cancer	0.00172	0.00178	CcSEcCtD
Orlistat—Abdominal pain—Carmustine—lymphatic system cancer	0.00171	0.00177	CcSEcCtD
Orlistat—Body temperature increased—Carmustine—lymphatic system cancer	0.00171	0.00177	CcSEcCtD
Orlistat—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00169	0.00175	CcSEcCtD
Orlistat—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00168	0.00175	CcSEcCtD
Orlistat—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00165	0.00172	CcSEcCtD
Orlistat—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00164	0.00171	CcSEcCtD
Orlistat—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00163	0.0017	CcSEcCtD
Orlistat—Body temperature increased—Vincristine—lymphatic system cancer	0.00163	0.00169	CcSEcCtD
Orlistat—Abdominal pain—Vincristine—lymphatic system cancer	0.00163	0.00169	CcSEcCtD
Orlistat—Urticaria—Mitoxantrone—lymphatic system cancer	0.00159	0.00166	CcSEcCtD
Orlistat—Hypersensitivity—Carmustine—lymphatic system cancer	0.00159	0.00165	CcSEcCtD
Orlistat—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00159	0.00165	CcSEcCtD
Orlistat—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00159	0.00165	CcSEcCtD
Orlistat—Vomiting—Bleomycin—lymphatic system cancer	0.00157	0.00164	CcSEcCtD
Orlistat—Infestation NOS—Methotrexate—lymphatic system cancer	0.00157	0.00163	CcSEcCtD
Orlistat—Infestation—Methotrexate—lymphatic system cancer	0.00157	0.00163	CcSEcCtD
Orlistat—Depression—Methotrexate—lymphatic system cancer	0.00156	0.00163	CcSEcCtD
Orlistat—Rash—Bleomycin—lymphatic system cancer	0.00156	0.00162	CcSEcCtD
Orlistat—Dermatitis—Bleomycin—lymphatic system cancer	0.00156	0.00162	CcSEcCtD
Orlistat—Asthenia—Carmustine—lymphatic system cancer	0.00155	0.00161	CcSEcCtD
Orlistat—Renal failure—Methotrexate—lymphatic system cancer	0.00154	0.0016	CcSEcCtD
Orlistat—Hypersensitivity—Vincristine—lymphatic system cancer	0.00152	0.00158	CcSEcCtD
Orlistat—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00148	0.00154	CcSEcCtD
Orlistat—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00148	0.00154	CcSEcCtD
Orlistat—Asthenia—Vincristine—lymphatic system cancer	0.00148	0.00154	CcSEcCtD
Orlistat—Diarrhoea—Carmustine—lymphatic system cancer	0.00148	0.00154	CcSEcCtD
Orlistat—Nausea—Bleomycin—lymphatic system cancer	0.00147	0.00153	CcSEcCtD
Orlistat—Asthenia—Mitoxantrone—lymphatic system cancer	0.00144	0.0015	CcSEcCtD
Orlistat—Dizziness—Carmustine—lymphatic system cancer	0.00143	0.00148	CcSEcCtD
Orlistat—Haemoglobin—Methotrexate—lymphatic system cancer	0.00141	0.00147	CcSEcCtD
Orlistat—Diarrhoea—Vincristine—lymphatic system cancer	0.00141	0.00147	CcSEcCtD
Orlistat—Hepatitis—Methotrexate—lymphatic system cancer	0.00141	0.00146	CcSEcCtD
Orlistat—Haemorrhage—Methotrexate—lymphatic system cancer	0.00141	0.00146	CcSEcCtD
Orlistat—Pharyngitis—Methotrexate—lymphatic system cancer	0.0014	0.00145	CcSEcCtD
Orlistat—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00139	0.00145	CcSEcCtD
Orlistat—Urethral disorder—Methotrexate—lymphatic system cancer	0.00138	0.00143	CcSEcCtD
Orlistat—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00137	0.00143	CcSEcCtD
Orlistat—Vomiting—Carmustine—lymphatic system cancer	0.00137	0.00143	CcSEcCtD
Orlistat—Dizziness—Vincristine—lymphatic system cancer	0.00136	0.00142	CcSEcCtD
Orlistat—Rash—Carmustine—lymphatic system cancer	0.00136	0.00142	CcSEcCtD
Orlistat—Dermatitis—Carmustine—lymphatic system cancer	0.00136	0.00141	CcSEcCtD
Orlistat—Headache—Carmustine—lymphatic system cancer	0.00135	0.00141	CcSEcCtD
Orlistat—Vomiting—Vincristine—lymphatic system cancer	0.00131	0.00136	CcSEcCtD
Orlistat—Rash—Vincristine—lymphatic system cancer	0.0013	0.00135	CcSEcCtD
Orlistat—Dermatitis—Vincristine—lymphatic system cancer	0.0013	0.00135	CcSEcCtD
Orlistat—Headache—Vincristine—lymphatic system cancer	0.00129	0.00134	CcSEcCtD
Orlistat—Nausea—Carmustine—lymphatic system cancer	0.00128	0.00133	CcSEcCtD
Orlistat—Vomiting—Mitoxantrone—lymphatic system cancer	0.00128	0.00133	CcSEcCtD
Orlistat—Immune system disorder—Methotrexate—lymphatic system cancer	0.00127	0.00132	CcSEcCtD
Orlistat—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00127	0.00132	CcSEcCtD
Orlistat—Rash—Mitoxantrone—lymphatic system cancer	0.00126	0.00132	CcSEcCtD
Orlistat—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00126	0.00131	CcSEcCtD
Orlistat—Headache—Mitoxantrone—lymphatic system cancer	0.00126	0.00131	CcSEcCtD
Orlistat—Alopecia—Methotrexate—lymphatic system cancer	0.00124	0.00129	CcSEcCtD
Orlistat—Mental disorder—Methotrexate—lymphatic system cancer	0.00123	0.00128	CcSEcCtD
Orlistat—Malnutrition—Methotrexate—lymphatic system cancer	0.00122	0.00127	CcSEcCtD
Orlistat—Nausea—Vincristine—lymphatic system cancer	0.00122	0.00127	CcSEcCtD
Orlistat—Dysgeusia—Methotrexate—lymphatic system cancer	0.0012	0.00125	CcSEcCtD
Orlistat—Nausea—Mitoxantrone—lymphatic system cancer	0.00119	0.00124	CcSEcCtD
Orlistat—Back pain—Methotrexate—lymphatic system cancer	0.00118	0.00123	CcSEcCtD
Orlistat—Vision blurred—Methotrexate—lymphatic system cancer	0.00115	0.0012	CcSEcCtD
Orlistat—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00114	0.00118	CcSEcCtD
Orlistat—Malaise—Methotrexate—lymphatic system cancer	0.0011	0.00115	CcSEcCtD
Orlistat—Vertigo—Methotrexate—lymphatic system cancer	0.0011	0.00114	CcSEcCtD
Orlistat—Cough—Methotrexate—lymphatic system cancer	0.00107	0.00111	CcSEcCtD
Orlistat—Convulsion—Methotrexate—lymphatic system cancer	0.00106	0.0011	CcSEcCtD
Orlistat—Chest pain—Methotrexate—lymphatic system cancer	0.00104	0.00108	CcSEcCtD
Orlistat—Myalgia—Methotrexate—lymphatic system cancer	0.00104	0.00108	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00104	0.00108	CcSEcCtD
Orlistat—Discomfort—Methotrexate—lymphatic system cancer	0.00103	0.00107	CcSEcCtD
Orlistat—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.001	0.00104	CcSEcCtD
Orlistat—Infection—Methotrexate—lymphatic system cancer	0.000993	0.00103	CcSEcCtD
Orlistat—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00098	0.00102	CcSEcCtD
Orlistat—Skin disorder—Methotrexate—lymphatic system cancer	0.000971	0.00101	CcSEcCtD
Orlistat—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000966	0.00101	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000911	0.000947	CcSEcCtD
Orlistat—Insomnia—Methotrexate—lymphatic system cancer	0.000904	0.00094	CcSEcCtD
Orlistat—Paraesthesia—Methotrexate—lymphatic system cancer	0.000898	0.000934	CcSEcCtD
Orlistat—Dyspepsia—Methotrexate—lymphatic system cancer	0.00088	0.000915	CcSEcCtD
Orlistat—Decreased appetite—Methotrexate—lymphatic system cancer	0.000869	0.000904	CcSEcCtD
Orlistat—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000863	0.000898	CcSEcCtD
Orlistat—Fatigue—Methotrexate—lymphatic system cancer	0.000862	0.000896	CcSEcCtD
Orlistat—Pain—Methotrexate—lymphatic system cancer	0.000855	0.000889	CcSEcCtD
Orlistat—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000824	0.000857	CcSEcCtD
Orlistat—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000817	0.00085	CcSEcCtD
Orlistat—Urticaria—Methotrexate—lymphatic system cancer	0.000794	0.000826	CcSEcCtD
Orlistat—Abdominal pain—Methotrexate—lymphatic system cancer	0.00079	0.000822	CcSEcCtD
Orlistat—Body temperature increased—Methotrexate—lymphatic system cancer	0.00079	0.000822	CcSEcCtD
Orlistat—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000736	0.000766	CcSEcCtD
Orlistat—Asthenia—Methotrexate—lymphatic system cancer	0.000717	0.000746	CcSEcCtD
Orlistat—Pruritus—Methotrexate—lymphatic system cancer	0.000707	0.000736	CcSEcCtD
Orlistat—Diarrhoea—Methotrexate—lymphatic system cancer	0.000684	0.000711	CcSEcCtD
Orlistat—Dizziness—Methotrexate—lymphatic system cancer	0.000661	0.000688	CcSEcCtD
Orlistat—Vomiting—Methotrexate—lymphatic system cancer	0.000636	0.000661	CcSEcCtD
Orlistat—Rash—Methotrexate—lymphatic system cancer	0.00063	0.000656	CcSEcCtD
Orlistat—Dermatitis—Methotrexate—lymphatic system cancer	0.00063	0.000655	CcSEcCtD
Orlistat—Headache—Methotrexate—lymphatic system cancer	0.000626	0.000651	CcSEcCtD
Orlistat—Nausea—Methotrexate—lymphatic system cancer	0.000594	0.000618	CcSEcCtD
